Physician profile
Jaime Floyd
NPI 1861012874
$4,122.34
in general payments reported to CMS, 2019-2025
14 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $612 · 2022: $614 · 2023: $1,665 · 2024: $857 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,832 · Consulting Fee: $64.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,832.11 |
| Consulting Fee | $64.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,315.73 | 2021-2024 | Tezspire, Airsupra, Fasenra |
| Octapharma USA, INC. | $890.96 | 2022-2025 | Cutaquig, Panzyga |
| Genzyme Corporation | $503.26 | 2022-2025 | |
| Glaxosmithkline, LLC. | $373.69 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $347.25 | 2023-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $149.00 | 2023-2025 | Takhzyro, Cuvitru |
| Amgen INC. | $124.44 | 2023 | Tezspire |
| Biocryst US Sales Co., LLC | $120.00 | 2023 | Orladeyo |
| Dermavant Sciences, INC. | $92.40 | 2023-2024 | Vtama |
| Pharming Healthcare, INC. | $85.76 | 2023 | Ruconest |
| E.R. Squibb & Sons, L.L.C. | $48.79 | 2023 | Zeposia |
| Hikma Pharmaceuticals USA | $28.55 | 2025 | Ryaltris |
| Adma Biomanufacturing LLC | $23.11 | 2024 | |
| Csl Behring | $19.40 | 2025 | Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.